• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Virios Therapeutics Inc. (Amendment)

    3/31/23 2:33:29 PM ET
    $VIRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VIRI alert in real time by email
    SC 13G/A 1 virios_sc13ga.htm SC 13G/A virios_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 2)

     

    Under the Securities Exchange Act of 1934

     

    Virios Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001

    (Title of Class of Securities)

     

    92829J104

    (CUSIP Number)

     

    44 Milton Avenue, Alpharetta, Georgia, 30009 (866) 620-8655, Angela Walsh, Sr. VP, Secretary, Treasurer

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    March 30, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐

    Rule 13d-1(b)

    ☒

    Rule 13d-1(c)

    ☐

    Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No.

    1.

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only).

    Brian Corday

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship of Place of Organization

     

    USA

     

    Number of

    Shares

    Beneficially

    Owned by Each

    Reporting Person

    With

    5.

    Sole Voting Power 

     

    1,263,198

    6.

    Shared Voting Power

     

    0

    7. 

    Sole Dispositive Power 

     

    1,263,198

    8.

    Shared Dispositive Power

     

    0

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,263,198

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    6.9%

    12.

    Type of Reporting Person (See Instructions)

     

    Individual

     

     
    2

     

     

    ITEM 1:

     

    (a) Name of Issuer:

    Virios Therapuetics, Inc.

    44 Milton Ave, Alpharetta, Georgia 30009

     

    ITEM 2:

     

    (a) Name of Person Filing: 

    Brian Corday

     

    (b) Address of Principal Business Office or, if None, Residence:

    415 Cullingworth Drive, Johns Creek, Georgia 30022

     

    (c) Citizenship:

    USA

     

    (d) Title of Class of Securities:

    Common Stock, par value $0.001

     

    (e) CUSIP Number:

    92829J104

     

     
    3

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a)

    ☐

    Broker or dealer registered under section15 of the Act (15 U.S.C. 78o).

    (b)

    ☐

    Bank as defined in section 3(a)(6) of the Act (15U.S.C. 78c).

    (c)

    ☐

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)

    ☐

    Investment company registered under section 8 of the Investment Company Act of 1940 (15U.S.C. 80a-8).

    (e)

    ☐

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)

    ☐

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)

    ☐

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    (h)

    ☐

    A savings associations as defined in Section3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (j)

    ☐

    Group, in accordance with §240.13d-1(b)(1)(ii)(J);

     

    ITEM 4: OWNERSHIP.

     

    (a) Amount beneficially owned: 1,263,198

     

    (b) Percent of class: 6.9%

     

    (c) Number of shares as to which the person has: 1,263,198

     

     

    (i)

    Sole power to vote or to direct the vote

     

    1,263,198

     

    (ii)

    Shared power to vote or to direct the vote

     

     

     

    (iii)

    Sole power to dispose or to direct the disposition of

     

    1,263,198

     

    (iv)

    Shared power to dispose or to direct the disposition of

     

     

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐ .

    Instruction. Dissolution of a group requires a response to this item.

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    ITEM 10: CERTIFICATIONS.

     

    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were

     

     
    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: March 30, 2023

    By:

    /s/ Brian Corday

     

     

     

    Signature

     

     

     

     

     

     

     

    Brian Corday

     

     

     

    Name/Title

     

     

     
    5
    Get the next $VIRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIRI

    DatePrice TargetRatingAnalyst
    12/15/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Virios Therapeutics Inc.

      SC 13D - Virios Therapeutics, Inc. (0001818844) (Subject)

      10/15/24 4:19:38 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virios Therapeutics Inc. (Amendment)

      SC 13G/A - Virios Therapeutics, Inc. (0001818844) (Subject)

      2/13/24 6:01:06 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Virios Therapeutics Inc. (Amendment)

      SC 13G/A - Virios Therapeutics, Inc. (0001818844) (Subject)

      11/14/23 1:40:08 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX")

      Strategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout 2H25Near-term catalyst with top-line results from the IMC-2 Long-COVID Phase 2a study expected in early 4Q24 Existing VIRI stockholders to be granted a contingent value right ("CVR") tied to potential milestone payments associated with any future corporate partneri

      10/7/24 7:05:00 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics Announces Second Quarter 2024 Financial Results

      - Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center's Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the second quarter ended June 30, 2

      8/8/24 9:15:00 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

      ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO

      8/1/24 9:41:56 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VIRI
    Financials

    Live finance-specific insights

    See more
    • SEC Form 4 filed by Pridgen William

      4 - Virios Therapeutics, Inc. (0001818844) (Issuer)

      2/28/24 1:14:56 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Thomas John C

      4 - Virios Therapeutics, Inc. (0001818844) (Issuer)

      2/28/24 1:09:44 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Whitley Richard James

      4 - Virios Therapeutics, Inc. (0001818844) (Issuer)

      2/28/24 1:04:06 PM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

      ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO

      8/1/24 9:41:56 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

      - Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. Key Highlights The BHC-202 3-arm study comparing two dose levels of the valacyc

      5/9/24 7:45:00 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

      ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and

      5/2/24 9:15:00 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Virios Therapeutics Inc.

      DEFA14A - Virios Therapeutics, Inc. (0001818844) (Filer)

      10/7/24 8:06:54 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virios Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Virios Therapeutics, Inc. (0001818844) (Filer)

      10/7/24 8:02:34 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Virios Therapeutics Inc.

      10-Q - Virios Therapeutics, Inc. (0001818844) (Filer)

      8/9/24 10:15:38 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VIRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Virios Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Virios Therapeutics with a rating of Buy and set a new price target of $12.00

      12/15/21 6:05:39 AM ET
      $VIRI
      Biotechnology: Pharmaceutical Preparations
      Health Care